启德医药ADC平台就21款药物达成130亿美元交易;艾伯维16亿美元押注分子胶降解剂...

新康界
25 Jan

本周热点回顾超130亿美元!启德医药授权FGFR3 ADC及ADC技术平台1月24日,启德医药在苏州研发总部举行了重大商务合作签约仪式,协议内容为与Biohaven、AimedBio合作开发FGFR3 ADC药物GQ1017(GQ1011)以及授权其创新生物偶联核心技术平台,“赋能”合作伙伴共计21个靶点的ADC药物创新,交易总金额超过130亿美元。具体合作情况为:启德医药与AimedBio达成...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10